Asia-Pacific IgG4-Related Disease Market – Industry Trends and Forecast to 2028

Market Analysis and Insights: Asia-Pacific IgG4-Related Disease Market

Asia-Pacific IgG4-related disease market is expected to gain significant growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the Asia-Pacific IgG4-related disease market is growing with a CAGR of 4.2% in the forecast period of 2021 to 2028 and is expected to reach USD 522.91 million by 2028 from USD 387.49 million in 2020. Several clinical trials in China are conducted for the treatment of IgG4-related disorders, and the availability of advanced diagnostic solutions are major drivers expected to drive the market's growth in the forecast period

A growing number of people are affected by IgG4-related disease, which demands highly effective and advanced treatment to minimize the risk. The healthcare systems need highly advanced drugs for numerous different types of IgG4-related diseases during the treatment of patients. Therefore, the major market players are highly focusing on product launches and product approvals. Additionally, the government and regulatory bodies are supporting market players by product approval.

The rising prevalence of IgG4 disorder can act as a driver to the Asia-Pacific IgG4-related disease market. At the same time, the complex etiology of the disease restrains the market’s growth. The growing awareness among the target population about this disease can be an opportunity for the market. In contrast, the lack of adequate reimbursement policies can pose a challenge to the market.

The Asia-Pacific IgG4-related disease market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief; our team will help you create a revenue impact solution to achieve your desired goal. 

The Asia-Pacific IgG4-Related Disease Market Scope and Market Size

The Asia-Pacific IgG4-related disease market is segmented on the basis of disease type, type, route of administration, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of disease type, the Asia-Pacific IgG4-related disease market is segmented into type 1 (IgG4-related) autoimmune pancreatitis (AIP), retroperitoneal fibrosis, IgG4-related tubulointerstitial nephritis (TIN), igg4-related sclerosing cholangitis IgG4-related dacryoadenitis and sialadenitis, IgG4-related pachymeningitis, IgG4-related thyroid disease, serum IgG4 concentration, and others.  In 2021, the IgG4-related dacryoadenitis and sialadenitis segment is expected to dominate the market due to rising healthcare expenditure.
• On the basis of type, the Asia-Pacific IgG4-related disease market is segmented into diagnostic and treatment. In 2021, the diagnostics segment is expected to dominate the market because of the rising incidence of IgG4-related diseases.
• On the basis of route of administration, the Asia-Pacific IgG4-related disease market is segmented into oral, parenteral, and others. In 2021, the parenteral segment is expected to dominate the market due to better patient compliance.
• On the basis of end-user, the Asia-Pacific IgG4-related disease market is segmented into hospitals, specialty clinics, others. In 2021, the hospital's segment is expected to dominate the market because of the surging pool of IgG4-related disease patients.
• On the basis of distribution channel, the Asia-Pacific IgG4-related disease market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. In 2021, the hospital pharmacy segment is expected to dominate the market owing to increased government funding.

Asia-Pacific IgG4-Related Disease Market Country Level Analysis

The Asia-Pacific IgG4-related disease market is analyzed, and market size information is provided based on disease type, type, route of administration, end-user, and distribution channel. The countries covered in the Asia-Pacific IgG4-related disease market report are Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and the Rest of Asia-Pacific.

Japan is expected to dominate the Asia-Pacific IgG4-related disease market due to the increasing prevalence in the region. Asia-Pacific is expected to grow with the highest CAGR in the forecast period due to increasing healthcare expenditure in the region.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.  

Rising healthcare expenditure and escalation in innovations and technologies in the Asia-Pacific igG4-related disease market are creating new opportunities for players

IgG4-related disease by disease type segment in Japan is expected to grow at the highest rate. It is dominating the Asia-Pacific region in the forecast period of 2021 to 2028 owing to several clinical trials undergoing in China to treat IgG-4 related disorders in the country.

The Asia-Pacific IgG4-related disease market also provides you with detailed market analysis for every country's growth in a particular industry with the Asia-Pacific IgG4-related disease market sales and the impact of advancement in the Asia-Pacific IgG4-related disease market, and changes in changes regulatory scenarios with their support for the Asia-Pacific IgG4-related disease market. The data is available for the historical period 2010 to 2019. 

Competitive Landscape and Asia-Pacific IgG4-Related Disease Market Share Analysis

Asia-Pacific IgG4-related disease market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, and technology lifeline curve. The above data points are only related to the companies’ focus on the Asia-Pacific IgG4-related disease market.

Major players covered in the Asia-Pacific IgG4-related disease report are Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Baxter, Viatris Inc., Amgen Inc., Fresenius Kabi USA (a subsidiary of Fresenius SE & Co. KGaA), Pfizer Inc., Cipla Inc., Celltrion Healthcare Co., Ltd., Amneal Pharmaceuticals LLC, Accord-UK Ltd., Ingenus Pharmaceuticals, among other domestic and Asia-Pacific players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies worldwide, further accelerating the Asia-Pacific IgG4-related disease market.

For instance,

• In March 2018, Hikma Pharmaceuticals PLC announced a 4-year Asia-Pacific partnership with Direct Relief, one of the world’s leading medical relief organizations, as part of its new corporate brand launch announced aimed to put better health within reach for people around the world. The commitment of funding for the coming years as well as the provision of quality medicines will enable. This will help the company to expand its business and make the product profile strong
• In June 2021, Celltrion Healthcare presented the first real-world data for Truxima (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress. This presentation allowed the company to expand its root in the IgG4-related market as both the companies are engaged in manufacturing IgG4-related disease treatment products

SKU-65949